Nintedanib for Idiopathic Pulmonary Fibrosis (IPF) and Non-Small Cell Lung Cancer (NSCLC)

Introduction to Nintedanib

• The American Thoracic Society recommends nintedanib at a dose of 150 mg twice daily for patients with IPF to slow disease progression, and as a second-line treatment option in combination with docetaxel for patients with adenocarcinoma NSCLC who have progressed after first-line chemotherapy 1, 2, 3

Mechanism of Action and Efficacy

• Nintedanib is an intracellular inhibitor of multiple tyrosine kinases that targets growth factor receptors including vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), and platelet-derived growth factor (PDGF) 1, 4
• Nintedanib significantly reduces the annual rate of decline in forced vital capacity (FVC) by approximately 125 ml compared to placebo, indicating slowed disease progression in IPF patients 4
• The drug reduces the risk of acute exacerbations of IPF (HR 0.16; 95% CI, 0.04-0.70) 1

Patient Selection and Treatment

• Nintedanib is indicated for patients with confirmed IPF diagnosis regardless of disease severity 1, 4
• Treatment should be initiated early in the disease course to preserve lung function 4, 3
• For advanced NSCLC of adenocarcinoma histology, nintedanib is administered at 200 mg twice daily in combination with docetaxel as second-line therapy 2

Adverse Effects and Management

• Gastrointestinal effects are most common, with diarrhea occurring in approximately 62% of patients taking nintedanib versus 18% on placebo 1
• Elevated liver enzymes (AST/ALT) may occur and require monitoring 5, 6
• For persistent diarrhea, temporary dose reduction to 100 mg twice daily or treatment interruption may be necessary 1, 4

Special Considerations

• Nintedanib is also suggested for treatment of progressive pulmonary fibrosis (PPF) in patients with non-IPF fibrotic interstitial lung diseases who have failed standard management 5, 6
• In patients with PPF, nintedanib reduced annual FVC decline by approximately 107 ml compared to placebo 5, 6
• The benefit varies by underlying disease type, with greater FVC preservation in CTD-related ILD (106.2 ml/yr), fibrotic NSIP (141.7 ml/yr), and fibrotic occupational lung disease (252.8 ml/yr) 6

Nintedanib Use in Radiation-Induced Pulmonary Fibrosis

Introduction to Nintedanib Treatment

• The American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Latin American Thoracic Association conditionally recommend nintedanib for progressive pulmonary fibrosis from various causes, which could include radiation-induced fibrosis if it meets progressive pulmonary fibrosis criteria, with a low to moderate quality of evidence 7

Defining Progressive Disease

• Radiation-induced pulmonary fibrosis would need to demonstrate progression defined by a decline in FVC ≥10% predicted within 24 months, or a decline in FVC 5-10% predicted plus worsening respiratory symptoms or increased fibrosis on imaging within 24 months 7

Expected Benefits in Progressive Pulmonary Fibrosis

• Nintedanib reduces annual FVC decline by approximately 107 ml compared to placebo in progressive pulmonary fibrosis patients, with a low to moderate quality of evidence 7
• It decreases the risk of interstitial lung disease progression 2.4-fold, with a low to moderate quality of evidence 7

Adverse Effects and Monitoring

• Abdominal pain is 4.2 times more frequent with nintedanib treatment 7
• Nausea is 3.1 times more frequent with nintedanib treatment 7
• Vomiting is 3.6 times more frequent with nintedanib treatment 7
• Weight loss is 3.7 times more frequent with nintedanib treatment 7
• Adverse events lead to permanent dose reduction 7.9 times more frequently than placebo 7
• Treatment discontinuation occurs 1.9 times more frequently with nintedanib 7
• AST elevation is 3.2 times more frequent with nintedanib treatment 7
• ALT elevation is 3.6 times more frequent with nintedanib treatment 7

Nintedanib-Associated Weight Loss

Adverse Effects and Clinical Significance

• Weight loss occurs 3.7 times more frequently in nintedanib-treated patients compared to placebo across all progressive pulmonary fibrosis populations 8
• Adverse events lead to permanent dose reduction 7.9 times more frequently with nintedanib than placebo 8
• Treatment discontinuation occurs 1.9 times more frequently with nintedanib 8

Monitoring and Management Recommendations

• The American College of Rheumatology/American College of Chest Physicians recommends monitoring for weight loss during nintedanib therapy 9
• Liver function tests should be performed monthly for 3 months, then every 3 months, while simultaneously monitoring for diarrhea and weight loss 9
• The American Thoracic Society recommends monitoring for weight loss during pirfenidone therapy, suggesting this is a class-wide concern for antifibrotics 9

Clinical Benefits and Recommendations

• The American Thoracic Society/European Respiratory Society/Japanese Respiratory Society/Latin American Thoracic Association conditionally recommends nintedanib for progressive pulmonary fibrosis 8

Nintedanib in ILD with UIP Pattern and Fibrosis

Adverse Effect Management and Special Populations

• The European Respiratory Society recommends reducing the dose of nintedanib to 100 mg twice daily for persistent diarrhea or significant GI symptoms, as this manages symptoms in most patients 10
• The American Thoracic Society suggests that nintedanib can be combined with mycophenolate mofetil in systemic sclerosis-associated ILD with UIP pattern, which may provide additive benefit, as demonstrated by the SENSCIS trial 10
• The National Institute for Health and Care Excellence advises against delaying treatment initiation, as early treatment preserves more lung function, and against discontinuing prematurely for diarrhea without attempting dose reduction to 100 mg twice daily 10
• The European Society of Rheumatology recommends aggressive supportive care, including GERD management with proton pump inhibitors, treatment of infections, and pulmonary rehabilitation, in addition to nintedanib treatment 10

Epidemiology and Clinical Impact of Nintedanib‑Related Adverse Effects in Idiopathic Pulmonary Fibrosis

Incidence of Diarrhea

• In clinical studies, persistent diarrhea was reported in approximately 62 %–76 % of patients receiving nintedanib, indicating that this gastrointestinal symptom is common and generally manageable with dose adjustment. 11

Relative Frequency of Weight Loss

• Weight loss occurs about 3.7‑fold more often in patients treated with nintedanib compared with control groups, highlighting the need for routine monitoring and nutritional support during therapy. 11

Hepatic Safety Considerations

• Clinically significant elevations in liver enzymes that do not resolve after dose reduction may warrant permanent discontinuation of nintedanib. This recommendation is based on observed hepatic adverse events in trial populations. 11

Adverse Event Profile of Nintedanib and Pirfenidone in Idiopathic Pulmonary Fibrosis

Gastrointestinal Adverse Events of Nintedanib

• Nausea occurs approximately 3.1‑fold more often in patients with idiopathic pulmonary fibrosis receiving nintedanib compared with placebo. 12, 13
• Vomiting is about 3.6‑fold more frequent with nintedanib than with placebo in this population. 12, 13
• Abdominal pain is reported roughly 4.2‑fold more often in nintedanib‑treated patients versus placebo. 12, 13
• Anorexia is observed 2.8‑fold more frequently in patients receiving nintedanib compared with placebo. 12

Metabolic and Nutritional Effects of Nintedanib

• Weight loss occurs about 3.7‑fold more often in idiopathic pulmonary fibrosis patients treated with nintedanib than in those receiving placebo. 12, 13

Hepatic Effects of Nintedanib

• Elevations of aspartate aminotransferase (AST) are approximately 3.2‑fold more common with nintedanib than with placebo. 12, 13
• Elevations of alanine aminotransferase (ALT) are about 3.6‑fold more frequent in the nintedanib group versus placebo. 12, 13

Treatment Modification and Discontinuation with Nintedanib

• Permanent dose reduction is required roughly 7.9‑fold more often for nintedanib than for placebo. 12, 13
• Overall treatment discontinuation due to adverse events occurs about 1.9‑fold more frequently with nintedanib compared with placebo. 12, 13

Respiratory Safety of Nintedanib

• No significant differences in respiratory adverse events (e.g., cough, dyspnea, bronchitis, nasopharyngitis) are observed between nintedanib and placebo in patients with idiopathic pulmonary fibrosis. 12

Serious Adverse Events

• The incidence of serious or severe adverse events does not differ significantly between nintedanib and placebo in this patient population. 12

Comparative Safety: Pirfenidone vs. Nintedanib

• Pirfenidone is associated with a lower rate of liver enzyme elevation compared with nintedanib in patients with idiopathic pulmonary fibrosis. 12

Overall Comparative Discontinuation Rates

• Across the first year of therapy, nintedanib leads to discontinuation due to adverse events in roughly 70 % of patients, whereas pirfenidone results in discontinuation in about 31 % of patients. 12

Nintedanib Dosing and Monitoring in Progressive Fibrosing Interstitial Lung Disease

Standard Dosing Recommendation

• The recommended regimen for nintedanib in progressive fibrosing ILD is 150 mg taken orally twice daily; a reduction to 100 mg twice daily is reserved only for patients who cannot tolerate the standard dose because of adverse effects, particularly gastrointestinal symptoms. 14

Initiation Strategy

• All eligible patients should be started on 150 mg twice daily (the approved therapeutic dose that demonstrated efficacy in clinical trials). 15
• In clinical trials, the 150 mg twice‑daily dose reduced the annual decline in forced vital capacity (FVC) by approximately 125 mL compared with placebo in idiopathic pulmonary fibrosis, and by about 102.7 mL per year in progressive fibrosing ILD. [14][15]

Dose Reduction Protocol

• Dose reduction to 100 mg twice daily should be implemented only when patients experience persistent adverse effects that cannot be adequately managed with supportive care. 16

Hepatotoxicity Monitoring

• Liver enzymes (AST/ALT) should be measured monthly for the first three months of therapy and thereafter every three months. 16

Combination Therapy Considerations

• Nintedanib may be co‑administered with mycophenolate mofetil in systemic sclerosis‑associated ILD, showing a similar adverse‑event profile to nintedanib alone. [14][16]
• The magnitude of FVC benefit with nintedanib is comparable regardless of concurrent mycophenolate mofetil use: an additional 26.3 mL/year when combined with mycophenolate versus 55.4 mL/year when used without it. 14

Monitoring Algorithm

• Baseline assessment: obtain liver function tests, record body weight, and perform a nutritional assessment. 16
• Months 1–3: conduct monthly liver enzyme tests and evaluate for diarrhea and weight loss. 16
• After month 3: continue liver enzyme monitoring every three months and maintain ongoing surveillance for gastrointestinal symptoms and weight changes. 16
• Throughout treatment: watch for respiratory infections and provide aggressive management of gastro‑esophageal reflux disease with proton‑pump inhibitors. 16

Nintedanib in Systemic Sclerosis‑Associated Interstitial Lung Disease and Safety Profile

Indications and Efficacy in SSc‑ILD

• The American College of Rheumatology approves nintedanib (150 mg twice daily) for systemic sclerosis‑associated interstitial lung disease, either as monotherapy or in combination with mycophenolate mofetil. Level A (regulatory approval) 17
• In the SENSCIS randomized controlled trial, nintedanib reduced the adjusted annual decline in forced vital capacity (FVC) to ‑52.4 mL/year versus ‑93.3 mL/year with placebo (p = 0.04), demonstrating a statistically significant slowing of disease progression. Level A (RCT) 17
• The treatment benefit was consistent irrespective of concurrent mycophenolate use: patients receiving mycophenolate experienced an additional 26.3 mL/year preservation of FVC, while those not on mycophenolate showed a 55.4 mL/year benefit. Level A (sub‑analysis of RCT) 17

Safety and Adverse Effects

• Diarrhea is reported in approximately 62–76 % of patients receiving nintedanib, compared with 18–32 % on placebo, indicating a markedly higher incidence of this gastrointestinal adverse event. Level A (RCT safety data) 17

Supportive Care Recommendations

• Aggressive management of gastro‑oesophageal reflux disease with proton‑pump inhibitors, together with prompt treatment of respiratory infections, is recommended to mitigate gastrointestinal and pulmonary complications during nintedanib therapy. Level C (expert opinion / review) 18

Nintedanib (Ofev) Guideline Recommendations for Interstitial Lung Disease

Guideline Endorsement and Regulatory Status

• The American Thoracic Society/European Respiratory Society/Japanese Respiratory Society/Latin American Thoracic Association (2022) give strong guideline support and FDA approval to nintedanib for idiopathic pulmonary fibrosis (IPF) and for progressive fibrosing interstitial lung diseases (ILDs). 19

Recommendation Strength for Progressive Pulmonary Fibrosis (PPF)

• The same 2022 ATS/ERS/JRS/ALAT guideline issues a conditional recommendation for nintedanib in patients with progressive pulmonary fibrosis, making it the only antifibrotic with formal endorsement for non‑IPF progressive fibrosing ILDs. 19, 20

Diagnostic Criteria for IPF

• Diagnosis of IPF should be based on the 2022 ATS/ERS criteria, employing high‑resolution CT and/or lung biopsy to confirm the pattern of usual interstitial pneumonia. 19, 21

Definition of Progressive Fibrosing ILD (PPF)

• PPF is defined as the presence of at least two of the following three criteria within the past year:
  
  • Worsening respiratory symptoms (e.g., increased dyspnea or cough). 22
  • Decline in forced vital capacity > 5 % predicted or decline in diffusing capacity for carbon monoxide > 10 % predicted. (criterion cited in guideline definition) 19, 22
  • Radiological progression on HRCT, such as new or increased traction bronchiectasis, ground‑glass opacity with traction bronchiectasis, reticulation, honeycombing, or lobar volume loss. 22

Treatment Initiation Once PPF Is Confirmed

• After confirming PPF, initiate nintedanib at 150 mg twice daily (the evidence‑based dose demonstrated efficacy across major trials). 19

Monitoring and Follow‑Up Protocol

• First 3 months: monitor liver enzymes, body weight, and gastrointestinal symptoms monthly.
• Thereafter: perform pulmonary function tests, weight check, and liver‑enzyme assessment every 3–6 months. This schedule is recommended by the 2022 ATS/ERS guideline. 22

Nintedanib for Systemic Sclerosis‑Associated ILD and Progressive Fibrosing ILDs

Systemic Sclerosis‑Associated Interstitial Lung Disease (SSc‑ILD)

• Nintedanib (150 mg twice daily) should be considered either as monotherapy or in combination with mycophenolate mofetil for patients with SSc‑ILD. 23
• In the SENSCIS trial, nintedanib reduced the adjusted annual decline in forced vital capacity (FVC) to ‑52.4 mL/year versus ‑93.3 mL/year with placebo (p = 0.04), indicating a clinically meaningful slowing of lung‑function loss. 23
• The treatment effect was consistent irrespective of concurrent mycophenolate use: an additional 26.3 mL/year of FVC preservation when nintedanib was added to mycophenolate, compared with 55.4 mL/year when nintedanib was used alone. 23
• The adverse‑event profile of nintedanib was similar whether it was administered alone or together with mycophenolate mofetil. 23

Progressive Fibrosing Interstitial Lung Disease (PF‑ILD) – Evidence from the INBUILD Trial

• The INBUILD trial demonstrated that nintedanib is effective across a range of autoimmune and fibrotic ILDs that meet progressive‑fibrosing criteria. 23
• Among 170 patients with autoimmune‑disease‑related ILDs enrolled in INBUILD, nintedanib reduced the annual FVC decline by 102.7 mL/year compared with placebo (p = 0.012), confirming a robust antifibrotic benefit in this heterogeneous population. 23

Monitoring Recommendations Supported by Trial Data

• Monthly body‑weight measurement is recommended during the first three months of therapy to detect early signs of gastrointestinal adverse effects and unintended weight loss. 23

Combination Therapy Safety

• For patients with SSc‑ILD, nintedanib can be safely combined with mycophenolate mofetil, with a comparable adverse‑event profile to nintedanib monotherapy. 23